VivaGel (SPL7013 Gel): a candidate dendrimer--microbicide for the prevention of HIV and HSV infection
about
Optimal management of genital herpes: current perspectivesNanoparticles as potential new generation broad spectrum antimicrobial agentsA holistic approach to targeting disease with polymeric nanoparticlesSPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humansProgress in antiretroviral drug delivery using nanotechnologyA review of nanotechnological approaches for the prophylaxis of HIV/AIDS.Imaging and drug delivery using theranostic nanoparticlesIdentification of a dendrimeric heparan sulfate-binding peptide that inhibits infectivity of genital types of human papillomaviruses.Emerging nanotechnology approaches for HIV/AIDS treatment and prevention.Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.Nanoparticle-based drug delivery to the vagina: a review.Current advances in polymer-based nanotheranostics for cancer treatment and diagnosisNanomedical engineering: shaping future nanomedicines.Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1.Non-specific microbicide product development: then and nowsiRNA-based topical microbicides targeting sexually transmitted infections.A modified zinc acetate gel, a potential nonantiretroviral microbicide, is safe and effective against simian-human immunodeficiency virus and herpes simplex virus 2 infection in vivo.Enhancement of human immunodeficiency virus type 1 replication is not intrinsic to all polyanion-based microbicides.Formulating a sulfonated antiviral dendrimer in a vaginal microbicidal gel having dual mechanisms of actionTheranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms.GATG dendrimers and PEGylated block copolymers: from synthesis to bioapplications.Recent trends on hydrogel based drug delivery systems for infectious diseasesRafts, Nanoparticles and Neural DiseaseInhibition of herpes simplex virus type 1 and type 2 infections by peptide-derivatized dendrimers.The role of nanotechnology in the treatment of viral infections.Nanoparticles: Emerging carriers for drug delivery.Nanotechnology and the future of condoms in the prevention of sexually transmitted infections.New Ways to Treat Tuberculosis Using Dendrimers as Nanocarriers
P2860
Q26746041-98AEDFA1-DC53-4CEB-BED6-F965DE96779AQ26795444-21AF3B74-B60F-4971-B9CA-BFBC67E7A5E2Q26865163-A149CC87-FD63-4C5A-94EE-A8D21E4E8680Q28740364-B87E3894-4586-45D4-9149-2AD9AA27F2B1Q30395011-0341B51D-287A-4728-8FBD-2C24D5A912E2Q30431343-727D583E-1A9A-4E34-A554-ACB598256D6CQ30449480-49BAB197-ACDF-4DC1-9BBE-32579A8F06E1Q33636333-43E32076-41DE-48DE-83E5-63D7B1BE90FAQ33819656-7D9F155E-36CB-43E0-A364-D0634DDF21B2Q33821090-E2849591-A69E-479F-91D3-87C229052E02Q34079533-BF892337-A6BD-4B16-AA3B-A3C8F9340ED6Q34783018-552F4BD8-AE1C-4B56-981D-424D520848D8Q35019550-DE55F5B5-14E1-4A3C-AED6-4AC81A0180E4Q35045703-B9ABE14A-191D-45AC-BDDE-4A7E8AA75B50Q35345283-D6D214F0-B1EF-48D7-A789-8780F919BDE4Q35766254-C75091E2-67FE-41E1-ABFD-0CA75B72412CQ37036620-48E1C284-B838-451E-A0B9-C300AA778EF4Q37274721-74B75235-B23D-4CBA-8DC0-E71536DCFC6EQ37374013-E09C657E-7F0C-4AB2-A8C2-4AAA7792C339Q37938830-02195758-BFAA-436D-9596-F158A00E66D1Q38227356-944A7B2D-4EE1-4873-BFEB-E2491738C17EQ38810357-578041B7-2FEB-4544-A557-13DFAD00D8EAQ39203564-77FF7A38-7BFB-4783-9B9F-AB8A0721CB4EQ39541397-0C9AF94A-3D97-4A96-8CFE-50825343A37DQ40106774-42FF660E-816D-4B3E-8E69-3848DD34DA90Q42009342-39A897D2-05B4-4C63-ABFB-6E401EA7B1C6Q54256212-7BE97936-EBCB-4347-AE69-4D8196EDC7B4Q57174607-B9EA88A9-2330-4E7E-AD77-1F27A2E12134
P2860
VivaGel (SPL7013 Gel): a candidate dendrimer--microbicide for the prevention of HIV and HSV infection
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
VivaGel (SPL7013 Gel): a candi ...... ntion of HIV and HSV infection
@en
VivaGel
@nl
type
label
VivaGel (SPL7013 Gel): a candi ...... ntion of HIV and HSV infection
@en
VivaGel
@nl
prefLabel
VivaGel (SPL7013 Gel): a candi ...... ntion of HIV and HSV infection
@en
VivaGel
@nl
P2093
P2860
P921
P1476
VivaGel (SPL7013 Gel): a candi ...... ntion of HIV and HSV infection
@en
P2093
Lawrence R Stanberry
Richard Rupp
Susan L Rosenthal
P2860
P304
P407
P577
2007-01-01T00:00:00Z